Simple. Fast. Discreet.
Wegovy is a prescription-only weight loss injection containing semaglutide, clinically proven to help reduce appetite and support long-term weight loss. At PPRX, Wegovy is prescribed by private UK-registered doctors following a quick online consultation and delivered directly to your door with full pharmacist support.
Wegovy is a once-weekly injectable medication used for weight management in adults who are overweight or obese. It contains semaglutide, a GLP-1 receptor agonist that works by regulating appetite, increasing feelings of fullness, and reducing food cravings. Wegovy is specifically licensed for weight loss and is different from Ozempic, which is primarily licensed for type 2 diabetes.
Wegovy works by mimicking the natural GLP-1 hormone in your body. This hormone targets the areas of the brain that control hunger and satiety, helping you feel full sooner and stay full for longer. Over time, this leads to reduced calorie intake and sustainable weight loss when combined with lifestyle changes.
Wegovy may be suitable for adults with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition such as high blood pressure or insulin resistance. A private online consultation is required to confirm suitability before treatment is approved.
0.25mg | £144.99
0.5mg | £149.99
1mg | £154.99
1.7mg | £209.99
2.4mg | £289.99
7.2mg | (coming soon)
Wegovy prices in the UK vary depending on dose strength and provider. Prices reflect:
The medication itself
Private prescription
Clinical review
Cold-chain packaging
Next Day UK delivery
You can view our transparent pricing here:
https://www.pprx.co.uk/wegovy-prices/
Wegovy (Semaglutide) is a once-weekly injectable prescription medicine used for weight management in adults who are overweight or obese. It works by regulating appetite, increasing feelings of fullness, and reducing food cravings, helping support long-term weight loss when combined with healthy lifestyle changes.
Key Benefits
Clinically proven to support significant weight loss when combined with diet and exercise. Helps reduce appetite and control cravings by acting on hunger-regulating areas of the brain. Once-weekly dosing for convenience and improved treatment adherence.
How To Use
Wegovy is injected under the skin (subcutaneously) once weekly, on the same day each week, at any time of day, with or without food. Treatment usually starts at a low dose and is gradually increased over time to reduce side effects. Always follow the instructions provided or refer to the patient information leaflet supplied with the medication.
Available Dosages
0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg & 7.2mg (coming soon)
Active Ingredient: Semaglutide
Administration: Subcutaneous injection
Novo Nordisk has announced the upcoming release of Wegovy 7.2mg, a higher-strength maintenance dose designed for patients who may require additional appetite suppression and weight-loss support. Wegovy 7.2mg is not yet available in the UK and will be offered subject to regulatory approval and prescribing guidance. Updates will be provided once the dose becomes available.
Although both Wegovy and Ozempic contain semaglutide, Wegovy is licensed specifically for weight loss and is prescribed at higher maintenance doses. Ozempic is licensed for diabetes but is sometimes prescribed off-label. Wegovy follows a structured dosing schedule designed for long-term weight management.
Buying Wegovy from PPRX is simple and discreet. Complete our online consultation, which is reviewed by a UK-registered doctor. If approved, your Wegovy prescription is issued privately and your medication is dispensed by our registered pharmacy and delivered with cold-chain packaging.
Yes, Wegovy is available in the UK via private prescription following a medical assessment.
No, Wegovy can be prescribed by private doctors through our online consultation.
Wegovy is injected once weekly using a pre-filled pen.
They contain the same active ingredient, but Wegovy is licensed and dosed specifically for weight loss.
Wegovy 7.2mg has been announced but is not yet available in the UK. It will be offered subject to regulatory approval and prescribing guidance. This page will be updated once available.
